Further, we examined the associations among this signature, sorafenib use, and common clinical characteristics such as sex, age, and the presence or absence of mutations in TP53 and CTNNB1. The findings from this study will supplement the existing literature on HCC by providing useful data regarding molecular diagnosis and precision treatment and will help in screening drug targets for HCC. This evidence concerns the gene TP53 and hepatocellular carcinoma.